Cite
116P Real-world outcomes of patients with metastatic non-small cell lung cancer receiving 2L+ atezolizumab-based treatments in Taiwan clinical practice
MLA
J. Shih, et al. “116P Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Receiving 2L+ Atezolizumab-Based Treatments in Taiwan Clinical Practice.” Journal of Thoracic Oncology, vol. 16, Apr. 2021, p. S761. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........df36315f188a096d180937612d89dbbb&authtype=sso&custid=ns315887.
APA
J. Shih, C-C. Wang, C-H. Kuo, S-G. Wu, J.-Y. Hung, T. Hsia, C. Chiang, C-Y. Su, & C-F. Chen. (2021). 116P Real-world outcomes of patients with metastatic non-small cell lung cancer receiving 2L+ atezolizumab-based treatments in Taiwan clinical practice. Journal of Thoracic Oncology, 16, S761.
Chicago
J. Shih, C-C. Wang, C-H. Kuo, S-G. Wu, J.-Y. Hung, T. Hsia, C. Chiang, C-Y. Su, and C-F. Chen. 2021. “116P Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Receiving 2L+ Atezolizumab-Based Treatments in Taiwan Clinical Practice.” Journal of Thoracic Oncology 16 (April): S761. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........df36315f188a096d180937612d89dbbb&authtype=sso&custid=ns315887.